- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04261569
Clinical Trial for Near Infrared Endoventricular Illumination for Neuroprotection in Very Early Cases of Parkinson's Disease (Ev-NIRT) (Ev-NIRT)
Parkinson's disease has only pharmacological (essentially dopaminergic) and surgical treatment (essentially high-frequency deep brain stimulation), that are symptomatically effective. none of them is curative, and has the ability to slow down the disease and to protect dopaminergic neurons from death by neurodegeneration. Experimental results, based on preclinical studies, suggest that brain illumination in the Near-InfraRed (NIR) range is likely to slow down this neurodegenerative process.
Thus, a medical device system (called Ev-NIRT) has been developed for 670 nm intracerebral illumination of the substantia nigra pars compacta (SNpc), and is planned to be tested for the treatment of Parkinson's disease.
In this pilot study the investigators will evaluate the feasibility and tolerance of surgery and brain illumination thanks to the Ev-NIRT medical device, in a group of 7 de novo Parkinson's patients implanted with the innovative medical device. Patients will be monitored for 4 years.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The level of neuroprotection induced by illumination at 670nm appears effective in preclinical studies, and justify the transfer into a clinical trial. The investigators currently have developed and produced implantable devices, to be implanted into the brain through a minimally invasive endoventricular route. The electrical energy required is supplied by the batteries adapted from those used for deep brain stimulation.
The feasibility of trans ventricular implantation is ensured by the experience gained by our team in the endoventricular stimulation of the posterior hypothalamus in the cluster headache.
In this clinical study, the investigators will evaluate the tolerance and safety of intraventricular surgical technic and illumination by the Ev-NIRT medical device implanted into the brain of 7 patients with Parkinson's disease. idiopathic, aged 25-65 years, at a very early stage (less than 2 years of evolution). The NIR illumination will begin immediately after surgery.
The investigators will also evaluate secondarily, the neuroprotective effect of this new treatment modality, by comparing the decrease of dopaminergic neurons by Positron Emission Tomography (PET)-scan using [11C]PE2I) tracer of implanted patients to that of a control group of 7 patients whose characteristics in terms of duration of evolution and clinical severity are identical, but who are not implanted, and therefore not exposed to NIR illumination.
The PET-scan-PE2I exam is conducted in both groups annually for 4 years (a total of 5 measurements) and compared to the PE2I PET obtained at the beginning of participation in the study. A group-wide comparison will be made between the NIR group and the control group.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Caroline SANDRE-BALLESTER, PhD
- Phone Number: 33 (0)4 38 78 28 51
- Email: CSandreballester@chu-grenoble.fr
Study Contact Backup
- Name: Cécile MORO, PhD
- Phone Number: 33 (0)4 38 78 06 11
- Email: cecile.moro@cea.fr
Study Locations
-
-
-
Grenoble, France, 38000
- Recruiting
- CLINATEC
-
Contact:
- Caroline SANDRE-BALLESTER, PhD
- Phone Number: 33 (0)4 38 78 28 51
- Email: CSandreballester@chu-grenoble.fr
-
Contact:
- Cécile MORO, PhD
- Phone Number: 33 (0)4 38 78 06 11
- Email: cecile.moro@cea.fr
-
Principal Investigator:
- Stephan CHABARDES, MD, PhD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Clinically diagnosed idiopathic Parkinson's disease according to MDS criteria developed by R.B. Postuma (Anang et al, Neurology, 2014)
- Dopaminergic denervation confirmed in PET [11C]PE2I with a decrease in tracer fixation at the striatum level of at least 30% on average compared to the white matter fixation of the cerebellum
- Patients willing to start dopaminergic treatment
Very early stage of the disease:
- Diagnosis of recent Parkinson's disease (less than two years after a neurologist's diagnosis)
- Hoehn and Yahr Stage 1 to 2
- Maximum 2 tremor on the MDS-UPDRS scale
- Naive of any anti-Parkinsonian treatment
- Between 25 and 65 years of age
- Score on Beck Depression Inventory (BDI) scale below the value of 20
- Easy handling of the French language in oral and written language
- Social security affiliates or beneficiaries of such a scheme
- Informed and written consent signed by the patient
Exclusion Criteria:
- All categories of protected persons: pregnant woman, parturient, breastfeeding mother, person deprived of liberty by judicial or administrative decision, person subject to a measure of legal protection, hospitalized for psychiatric disorder
- Carcinological history in the previous 5 years, not stabilized
- Uncontrolled medical condition that may lead to complications
- Preoperative brain Magnetic Resonance Imaging (MRI) showing brain damage that may be responsible for Parkinson's syndrome or a significant surgical risk (e.g. vascular malformation)
- Surgical or anesthetic contraindication
- History of brain infection with herpes virus
- Contraindication to MRI (claustrophobia, non-compatible mri metal prosthesis, etc.)
- Predictable need for frequent use of MRI scans after surgery
- Unstabilized psychotropic treatment
- Patient with cognitive impairment at the outset of illness (Montreal Cognitive Assessment (MoCA) score - 26)
- Atypias suspecting atypical Parkinson's syndrome
- Chronic treatment with L-Dopa or dopamine agonist
- Presence of another serious pathology (major depressive episode, suicidal patient, active psychosis ...)
- Participation in another interventional clinical trial
- Wearing pace makers other than brain
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Illuminated arm
patients with intraventricular near-infrared light illumination
|
Endoventricular near infra red treatment : Intraventricular pulsed, chronic, cyclic, near-infrared illumination of the Central Nervous System (CNS) at 150 Hz, 15 mW, 1 minute ON and 5 minutes OFF
|
No Intervention: control arm
patients without any medical device
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of Ev-NIRT Treatment on Emergent Adverse Events (Tolerance) after surgical intervention and NIR illumination following the implantation of the Ev-NIRT medical device
Time Frame: 4 years
|
Emergent Adverse Events [Safety and Tolerability]
|
4 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Characterization of annual neuronal loss observed by decrease in tracer fixation at the striatum level
Time Frame: 4 years
|
Annual measurement of dopaminergic denervation in Positron Emission Tomography (PET) using [11C]PE2I tracer fixation at the striatum level in percentage compared to the white matter fixation of the cerebellum
|
4 years
|
Evaluation of the motor clinical signs progression
Time Frame: 4 years
|
Scores on the Movement Disorder Society-Sponsored Revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS scale sections II, III and IV) [0-100% : higher scores mean worse outcome]
|
4 years
|
Evaluation of the non-motor bahavioral signs progression
Time Frame: 4 years
|
Scores on the non-motor scales Behavioral Evaluation in Parkinson's disease (ECMP) [0-4 : higher scores mean worse outcome]
|
4 years
|
Evaluation of the non-motor clinical signs progression
Time Frame: 4 years
|
Scores on the non-motor scales Lille Apathy Rating Scale (LARS) [-4/+4 : higher scores mean worse outcome]
|
4 years
|
Evaluation of depression signs progression
Time Frame: 4 years
|
Scores on the non-motor scales Beck Depression Inventory (BDI-II) [0-3 : higher scores mean worse outcome]
|
4 years
|
Evaluation of the non-motor symptoms signs progression
Time Frame: 4 years
|
Scores on the non-motor scales Non Motor Symptoms scale (NMS) [0-30 : higher scores mean better outcome]
|
4 years
|
Comparison between the date of diagnosis and the date of introduction of substitution therapy with dopaminergic drugs or dopamine agonists
Time Frame: 4 years
|
Time period between the date of diagnosis and the date of introduction of dopaminergic substitute therapy or dopaminergic agonists
|
4 years
|
Evolution of this prescription of substitution therapy over the duration of study
Time Frame: 4 years
|
Follow up of dosage of dopaminergic substitute therapy or dopaminergic agonists
|
4 years
|
Assessment in both groups of the time it takes for the onset of different motor symptoms (including tremor, akinesia and stiffness, speech, walking and balance disorders) and not motor symptoms of Parkinson's disease in relation to initial diagnosis.
Time Frame: 4 years
|
Time period between the date of diagnosis and the date of onset of different motor and non-motor symptoms objectified by an increase in item scores specific to these symptoms on the Movement Disorder Society-Sponsored Revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS scale) passed into OFF drug [0-100% : higher scores mean worse outcome]
|
4 years
|
Evolution of the quality of life of patients in both groups
Time Frame: 4 years
|
Parkinson Disease Quotation (PDQ-39) quiz score [0-4 : higher scores mean worse outcome]
|
4 years
|
Evolution of walking speed in both patient groups
Time Frame: 4 years
|
Right and left foot speed measured during a walking task on the Vicon platform without and with dopaminergic treatment
|
4 years
|
Evolution of walking parameters in both patient groups
Time Frame: 4 years
|
Score in the "freezing of gait" questionnaire [0-24 : higher scores mean worse outcome] without and with dopaminergic treatment
|
4 years
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Stephan CHABARDES, MD, PhD, University Hospital, Grenoble
Publications and helpful links
General Publications
- Johnstone DM, Moro C, Stone J, Benabid AL, Mitrofanis J. Turning On Lights to Stop Neurodegeneration: The Potential of Near Infrared Light Therapy in Alzheimer's and Parkinson's Disease. Front Neurosci. 2016 Jan 11;9:500. doi: 10.3389/fnins.2015.00500. eCollection 2015.
- Chabardes S, Carron R, Seigneuret E, Torres N, Goetz L, Krainik A, Piallat B, Pham P, David O, Giraud P, Benabid AL. Endoventricular Deep Brain Stimulation of the Third Ventricle: Proof of Concept and Application to Cluster Headache. Neurosurgery. 2016 Dec;79(6):806-815. doi: 10.1227/NEU.0000000000001260.
- Darlot F, Moro C, El Massri N, Chabrol C, Johnstone DM, Reinhart F, Agay D, Torres N, Bekha D, Auboiroux V, Costecalde T, Peoples CL, Anastascio HD, Shaw VE, Stone J, Mitrofanis J, Benabid AL. Near-infrared light is neuroprotective in a monkey model of Parkinson disease. Ann Neurol. 2016 Jan;79(1):59-75. doi: 10.1002/ana.24542. Epub 2015 Dec 12.
- Moro C, El Massri N, Darlot F, Torres N, Chabrol C, Agay D, Auboiroux V, Johnstone DM, Stone J, Mitrofanis J, Benabid AL. Effects of a higher dose of near-infrared light on clinical signs and neuroprotection in a monkey model of Parkinson's disease. Brain Res. 2016 Oct 1;1648(Pt A):19-26. doi: 10.1016/j.brainres.2016.07.005. Epub 2016 Jul 7.
- Reinhart F, Massri NE, Chabrol C, Cretallaz C, Johnstone DM, Torres N, Darlot F, Costecalde T, Stone J, Mitrofanis J, Benabid AL, Moro C. Intracranial application of near-infrared light in a hemi-parkinsonian rat model: the impact on behavior and cell survival. J Neurosurg. 2016 Jun;124(6):1829-41. doi: 10.3171/2015.5.JNS15735. Epub 2015 Nov 27.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 38RC19.098
- 2019-A02097-50 (Other Identifier: ANSM ID RCB)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Very Early Stage of Parkinson's Disease
-
National Yang Ming UniversityUnknownEarly Onset Parkinson Disease | Early Stage Parkinson Disease
-
UCB Biopharma SRLActive, not recruitingEarly-stage Parkinson's DiseaseUnited States, Canada, France, Germany, Italy, Netherlands, Poland, Spain, United Kingdom
-
UCB PharmaCompletedEarly-Stage Parkinson's DiseaseUnited States, Canada
-
UCB PharmaCompletedEarly Stage Parkinson's DiseasePoland, United Kingdom, Germany, Spain, Switzerland, Belgium, South Africa, New Zealand, Czech Republic, Austria, Hungary, Australia, Italy, Israel, Sweden, Norway, Croatia, Netherlands, Finland, France
-
Ligand PharmaceuticalsCompletedEarly Stage Parkinson's DiseaseUnited States
-
Solvay PharmaceuticalsCompletedEarly Stage Parkinson's DiseaseUnited States, Argentina, Belgium, Bulgaria, Canada, Chile, Colombia, Croatia, Finland, India, Israel, Mexico, New Zealand, Peru, Romania, Russian Federation, Serbia, Slovakia, South Africa, Sweden, Ukraine
-
QualissimaH. Lundbeck A/STerminatedEarly-stage Parkinson's Disease
-
Solvay PharmaceuticalsCompletedEarly Stage Parkinson's DiseaseUnited States, Australia, Czech Republic, Estonia, Germany, India, Italy, Lithuania, Malaysia, Netherlands, Poland, Portugal, South Africa, Taiwan, Thailand
-
Solvay PharmaceuticalsCompletedEarly Stage Parkinson's DiseaseUnited States, Argentina, Belgium, Bulgaria, Canada, Chile, Colombia, Croatia, Finland, India, Israel, Mexico, New Zealand, Peru, Romania, Russian Federation, Serbia, Slovakia, South Africa, Sweden, Ukraine
-
Eastern Hepatobiliary Surgery HospitalCompletedHepatocellular Carcinoma | Very-early StageChina
Clinical Trials on Ev-NIRT
-
University of Colorado, DenverChildren's Hospital ColoradoRecruiting
-
Evolva SATerminated
-
McGuire InstituteDentsply Sirona ImplantsRecruitingPartially Edentulous Maxilla or MandibleUnited States
-
National Taiwan University HospitalUnknownAtrophy of Edentulous Alveolar RidgeTaiwan
-
Peking UniversityRecruitingAdvanced or Late Stage Gastrointestinal CancerChina
-
Dentsply Sirona Implants and ConsumablesCompletedDental ImplantsUnited States, Belgium, Canada, Finland, Germany, Sweden
-
Dentsply Sirona Implants and ConsumablesActive, not recruitingJaw, Edentulous, PartiallyUnited States, Belgium, Germany, Italy, Netherlands
-
Dentsply Sirona Implants and ConsumablesActive, not recruitingJaw, EdentulousGermany, Switzerland, United Kingdom
-
AtaCor Medical, Inc.CompletedVentricular Fibrillation | Ventricular Tachycardia | Ventricular ArrhythmiaParaguay
-
Shen LinRecruitingImmunotherapy | Advanced Gastric AdenocarcinomaChina